Surya Nallari, MD
Geriatric Medicine · Demotte, INNPI 1760478853
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 37 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$142
- Novo Nordisk$134
- Sanofi-aventis U.S. LLC$125
- Amarin Pharma, Inc.$89
- Pfizer$81
- EKOS Corporation$75
- plus $158 from 10 others
What the payments were for
- Food & beverage$73992%
- Education$658%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 2 | $142 |
| Novo Nordisk | 7 | $134 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Amarin Pharma, Inc. | 7 | $89 |
| Pfizer | 6 | $81 |
| EKOS Corporation | 1 | $75 |
| AstraZeneca | 2 | $28 |
| Johnson & Johnson | 2 | $28 |
| Novartis | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
| GSK | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| AbbVie | 1 | $12 |
| Vivus LLC | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$125
- KRYSTEXXA$125
How this compares
$803 in reported general payments places this provider in the 70th percentile of 70 geriatric medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 12 | $98,151 |
| EliquisApixaban | 307 | $94,763 |
| NuplazidPimavanserin Tartrate | 23 | $60,034 |
| TradjentaLinagliptin | 94 | $26,948 |
| RestasisCyclosporine | 38 | $13,053 |
| EntrestoSacubitril/Valsartan | 32 | $10,524 |
| ProcritEpoetin Alfa | 20 | $9,333 |
| Escitalopram Oxalate | 270 | $8,105 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $6,750 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,504 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 60 | $6,149 |
| Budesonide | 24 | $4,932 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $4,896 |
| MultaqDronedarone Hcl | 22 | $4,392 |
| MovantikNaloxegol Oxalate | 20 | $4,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $94,763307 claims |
| Boehringer IngelheimTradjenta | $14 | $26,94894 claims |
| AbbVieRestasis, Namzaric | $12 | $19,80261 claims |
| Johnson & JohnsonProcrit, Xarelto | $28 | $12,33431 claims |
| NovartisEntresto | $15 | $10,52432 claims |
| GSKBreo Ellipta | $13 | $6,50415 claims |
| Sanofi-aventis U.S. LLCMultaq | $125 | $4,39222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 70 geriatric medicine providers in Indiana.
Other geriatric medicine in Demotte
- Malaz BoustaniIndianapolis$188K
- Gregory SpanglerKokomo$31K
- Jodie HarperIndianapolis$27K
- Karl SashEvansville$26K
- Arnold del PilarMishawaka$25K
- Lauren DandurandMerrillville$11K
- Jack BartoszekMishawaka$7K
- Elton AmosIndianapolis$7K
- Kofi QuistIndianapolis$5K
- Robert LebowIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.